Telescope Innovations Corp. announced that the Korean Pharmaceutical and Biopharmaceutical Manufacturers Association (KPBMA) has bought one of Telescope's Self-Driving Lab (SDL) platforms. The platform will be set up at a new research and development facility in Seoul in just a few weeks. The facility is designed to help speed up the development of new pharmaceuticals.
A Self-Driving Lab (SDL) is an automated system that uses robots, data analysis tools, and AI to run experiments and improve them automatically in a continuous process. It can operate nonstop and adjust experiments in real time. This allows the SDL to finish and improve many experiments much faster and more consistently than manual lab work. SDLs can speed up research and development, potentially cutting years off traditional timelines and making it faster to bring new products to market.
KPBMA is the largest trade group for Korea's pharmaceutical and biotech industry, with 300 member companies, both local and international. KPBMA's main goals are to support research and development (R&D) and encourage innovation in drug manufacturing. This year, KPBMA started its first Self-Driving Lab (SDL) project through its Convergence AI Institute for Drug Discovery (CAIID) to promote automation and AI-based experimentation.
Telescope's SDLs will be part of a training center to show off new technology, provide education, and help researchers learn how to use this new R&D method. Telescope will set up the SDL in the next few weeks, and after that, they will work together with KPBMA on a long-term partnership to expand SDL use in Korea's pharmaceutical industry.
Executive Statement
According to Junhee Pyo, CAIID Vice Chief., they anticipate that this Self-Driving Lab will bring significant innovation to new drug development processes in Korea. They also look forward to active global collaboration to facilitate technological exchange in this rapidly advancing field.
